Markets

Edge Therapeutics prices IPO at $11, far below the range

Edge Therapeutics, which is developing a sustained-release therapy for limiting brain injury after aneurysms, raised $80 million by offering 7.3 million shares at $11, far below the range of $14 to $16. Edge Therapeutics plans to list on the Nasdaq under the symbol EDGE. Edge Therapeutics initially filed confidentially on 3/21/2014. Leerink Partners and Credit Suisse acted as lead managers on the deal.

The article Edge Therapeutics prices IPO at $11, far below the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PDSB

Other Topics

IPOs

Latest Markets Videos